Abbott announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.
Abbott licenses biomarkers for use in differentiating aggressive from nonaggressive prostate cancer